TRIAL TO COMPARE ADJUVANT ADRIAMYCIN AND CYCLOPHOSPHAMIDE FOLLOWED BY TAXOTERE

比较阿霉素和环磷酰胺佐剂随后泰索帝的试验

• 批准号: 7376247
• 负责人: WILLIAM MCKINNON
• 金额: $ 0.17万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376247
• 关键词: TRIAL; COMPARE; ADJUVANT; ADRIAMYCIN; CYCLOPHOSPHAMIDE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of this phase III trial are to determine whether four cycles of post-operative Adriamycin (A:60mg/m2), Taxotere (T:60mg/m2), and Cyclophosphamide (C:600mg/m2) administered concurrently will more effectively prolong disease-free survival (DFS) and overall survival (S) of patients with node-positive breast cancer than will four cycles of AC (A:60mg/m2 and C:600mg/m2) followed by four cycles of T (100mg/m2); and if four cycles of post-operative AT (A:60mg/m2 and T:60mg/m2) is at least as efficacious as the above two regimens containing cyclophosphamide.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本III期试验的主要目的是确定4个周期的术后阿霉素（A：60 mg/m2）、泰索帝（T：60 mg/m2）和环磷酰胺（C：600 mg/m2）同时给药是否比4个周期的AC（A：60 mg/m2和C：600 mg/m2）随后4个周期的T（100 mg/m2）更有效地延长淋巴结阳性乳腺癌患者的无病生存期（DFS）和总生存期（S）;以及4个周期的术后AT（A：60 mg/m2和T：60 mg/m2）是否至少与上述两种含环磷酰胺的方案一样有效。